MPI KRYPTON 81M GENERATOR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MPI KRYPTON 81M GENERATOR (MPI KRYPTON 81M GENERATOR).
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
| Metabolism | Krypton-81m is an inert gas; it is not metabolized. It is cleared from the lungs by exhalation and decays with a physical half-life of 13 seconds. |
| Excretion | Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally). |
| Half-life | Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation. |
| Protein binding | Negligible (<1%); krypton-81m is an inert gas with no significant protein binding. |
| Volume of Distribution | Primarily confined to lung airspaces and blood; not meaningfully distributed to tissues. Apparent Vd ~0.5 L/kg (as a gas, distributes in air and blood). |
| Bioavailability | Inhalation: 100% (directly reaches pulmonary circulation). |
| Onset of Action | Inhalation: Immediate (seconds) upon reaching pulmonary circulation. |
| Duration of Action | Imaging window: 20-30 seconds due to rapid decay; clinical effect (imaging) ends within 1 minute. |
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
| Dosage form | GAS |
| Renal impairment | No specific GFR-based dose modification required. Krypton-81m decays by electron capture to rubidium-81m with a half-life of 13 seconds, and elimination is primarily via radioactive decay, not renal excretion. |
| Liver impairment | No dose adjustment necessary. Krypton-81m is an inert gas eliminated by pulmonary excretion; hepatic function does not affect pharmacokinetics. |
| Pediatric use | Pediatric doses are typically calculated based on body weight using the formula: Dose (MBq) = [Adult Dose (MBq) × Weight (kg)] / 70. For ventilation studies: 5-10 MBq/kg (0.14-0.27 mCi/kg) intravenously or inhaled. Maximum administered activity should not exceed 400 MBq (10.8 mCi). For neonates and infants, reduce to lowest effective dose. |
| Geriatric use | No specific dose adjustment required in elderly patients. Use minimal dose necessary to obtain diagnostic information, as with any radiopharmaceutical. Consider age-related decline in pulmonary function, but no pharmacokinetic changes expected due to radioactive gas characteristics. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MPI KRYPTON 81M GENERATOR (MPI KRYPTON 81M GENERATOR).
| Breastfeeding | Krypton-81m decays rapidly and has minimal transfer into breast milk. M/P ratio not determined due to negligible milk concentrations. The American College of Radiology recommends no special interruption of breastfeeding after administration, but to minimize infant radiation exposure, pumping and discarding milk for 1-2 hours post-procedure is a conservative option. |
| Teratogenic Risk | Krypton-81m is a radioactive gas with a very short half-life (13 seconds). Due to its rapid decay and minimal systemic absorption, fetal radiation exposure is negligible when used per standard protocols. No teratogenic effects have been reported; however, as with any radiopharmaceutical, exposure should be minimized in pregnancy, especially during organogenesis (first trimester). The benefit-risk balance must be assessed. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component of the generator or product.
| Precautions | This product contains radioactive material; ensure safe handling and disposal. Use in pregnancy only if benefit justifies risk. In women of childbearing potential, consider possibility of pregnancy. Strict adherence to radiation safety procedures is required. |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond standard radiation safety precautions. Verify pregnancy status before administration. Monitor for any adverse reactions during inhalation, though rare. |
| Fertility Effects | No known effects on human fertility. As a short-lived radionuclide, it does not accumulate in reproductive organs. Animal studies have not been conducted, but negligible gonadal radiation exposure is expected. |